Toripalimab to fortify Dr Reddy’s oncology portfolio

11 December 2024

Indian drugmaker Dr Reddy’s Laboratories (BSE: 500124) has recently become the first Indian company to launch checkpoint inhibitor Zytorvi (toripalimab) in collaboration with Shanghai Junshi Biosciences (SSE: 688180).

Zytorvi is a pioneering immuno-oncology therapy for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). This marks a transformative moment, bringing a next-generation PD-1 inhibitor to India and addressing significant unmet medical needs. With the launch, Dr Reddy's has positioned itself in the forefront of the commercialization of oncology innovation, says pharma analytics company GlobalData.

According to GlobalData's Pharmaceutical Intelligence Center, China is the only country with seven available treatments, including toripalimab, for NPC in the Asia-Pacific (APAC) region. India is now the second country in the region to offer specific treatment for this rare type of head and neck cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK